Enzymatic features of the glucose metabolism in tumor cells

FEBS Journal

Volumn 278, Issue 14, 2011, Pages 2436-2459

  Herling, Anique ^a   König, Matthias ^a   Bulik, Sascha ^a   Holzhütter, Hermann Georg ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

aerobic; cancer; enzyme; glucose; glycolysis; isozymes; metabolism; TCA cycle; tumor; Warburg effect

Indexed keywords

6 PHOSPHOFRUCTO 2 KINASE; 6 PHOSPHOFRUCTOKINASE; ACETYL COENZYME A; ADENOSINE TRIPHOSPHATE; ENOLASE; FATTY ACID SYNTHASE; FRATAXIN; FRUCTOSE 2,6 BIPHOSPHATASE; FRUCTOSE BISPHOSPHATASE; FRUCTOSE BISPHOSPHATE ALDOLASE; GLUCOSE; GLUCOSE 6 PHOSPHATE DEHYDROGENASE; GLUCOSE 6 PHOSPHATE ISOMERASE; GLUCOSE TRANSPORTER 1; GLUCOSE TRANSPORTER 4; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; GLYCOGEN SYNTHASE; HEXOKINASE; LACTATE DEHYDROGENASE; LACTIC ACID; PHOSPHOGLUCOMUTASE; PHOSPHOGLYCERATE KINASE; PHOSPHOGLYCERATE MUTASE; PYRUVATE KINASE; PYRUVIC ACID; REACTIVE OXYGEN METABOLITE; TRANSALDOLASE; TRANSKETOLASE; TRIOSEPHOSPHATE ISOMERASE; UNCLASSIFIED DRUG;

AEROBIC METABOLISM; BREAST CANCER; CANCER GROWTH; CARCINOGENESIS; CELL CYCLE PHASE; CELL METABOLISM; CELL PROLIFERATION; CELL TRANSFORMATION; COLON CANCER; CYTOSOL; ENERGY METABOLISM; ENZYME ACTIVITY; ENZYME MECHANISM; ENZYME REGULATION; ENZYME RELEASE; ENZYME SPECIFICITY; ENZYME SUBSTRATE; ENZYME SUBSTRATE COMPLEX; GENE OVEREXPRESSION; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; GLYCOGEN METABOLISM; GLYCOLYSIS; HUMAN; INTRACELLULAR TRANSPORT; LEUKEMIA CELL; LIPOGENESIS; LIVER CANCER; MELANOMA; MELANOMA CELL; METABOLIC REGULATION; MITOCHONDRION; NONHUMAN; OXIDATIVE PHOSPHORYLATION; PENTOSE PHOSPHATE CYCLE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RESPIRATORY CHAIN; REVIEW; TRANSCRIPTION REGULATION; TUMOR CELL; TUMOR MICROENVIRONMENT; UTERINE CERVIX CARCINOMA;

ANIMALS; ENERGY METABOLISM; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUCOSE; HUMANS; ISOENZYMES; KINETICS; MITOCHONDRIA; NEOPLASM PROTEINS; NEOPLASMS;

EID: 79959927716     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/j.1742-4658.2011.08174.x     Document Type: Review

References (239)

1. Jiang P, Du W, Wang X, Mancuso A, Gao X, Wu M, &, Yang X, (2011) p53 regulates biosynthesis through direct inactivation of glucose-6-phosphate dehydrogenase. Nat Cell Biol 13, 310-316.
2. Warburg O, Wind F, &, Negelein E, (1927) The metabolism of tumors in the body. J Gen Physiol 8, 519-530.
3. Hinkle PC, (2005) P/O ratios of mitochondrial oxidative phosphorylation. Biochim Biophys Acta 1706, 1-11. (Pubitemid 40037758)
4. Hinkle PC, Kumar MA, Resetar A, &, Harris DL, (1991) Mechanistic stoichiometry of mitochondrial oxidative phosphorylation. Biochemistry 30, 3576-3582.
5. Sussman I, Erecinska M, &, Wilson DF, (1980) Regulation of cellular energy metabolism: the Crabtree effect. Biochim Biophys Acta 591, 209-223.
6. Svaninger G, Gelin J, &, Lundholm K, (1989) The cause of death in non-metastasizing sarcoma-bearing mice. A study with relevance for tumor treatment experiments in mice. Eur J Cancer Clin Oncol 25, 1295-1302. (Pubitemid 19234446)
7. Wei S, Kulp SK, &, Chen CS, (2010) Energy restriction as an antitumor target of thiazolidinediones. J Biol Chem 285, 9780-9791.
8. Helmlinger G, Yuan F, Dellian M, &, Jain RK, (1997) Interstitial pH and pO2 gradients in solid tumors in vivo: high-resolution measurements reveal a lack of correlation. Nat Med 3, 177-182. (Pubitemid 27064702)
9. Semenza GL, (2008) Tumor metabolism: cancer cells give and take lactate. J Clin Invest 118, 3835-3837.
10. Bonuccelli G, Tsirigos A, Whitaker-Menezes D, Pavlides S, Pestell RG, Chiavarina B, Frank PG, Flomenberg N, Howell A, Martinez-Outschoorn UE, et al. (2010) Ketones and lactate 'fuel' tumor growth and metastasis: evidence that epithelial cancer cells use oxidative mitochondrial metabolism. Cell Cycle 9, 3506-3514.
11. + exchanger in metastasis. Nat Rev Cancer 5, 786-795. (Pubitemid 41400778)
12. Samudio I, Fiegl M, McQueen T, Clise-Dwyer K, &, Andreeff M, (2008) The Warburg effect in leukemia-stroma cocultures is mediated by mitochondrial uncoupling associated with uncoupling protein 2 activation. Cancer Res 68, 5198-5205.
13. Brand KA, &, Hermfisse U, (1997) Aerobic glycolysis by proliferating cells: a protective strategy against reactive oxygen species. FASEB J 11, 388-395. (Pubitemid 27193945)
14. Schulz TJ, Thierbach R, Voigt A, Drewes G, Mietzner B, Steinberg P, Pfeiffer AF, &, Ristow M, (2006) Induction of oxidative metabolism by mitochondrial frataxin inhibits cancer growth: Otto Warburg revisited. J Biol Chem 281, 977-981.
15. Le A, Cooper CR, Gouw AM, Dinavahi R, Maitra A, Deck LM, Royer RE, Vander Jagt DL, Semenza GL, &, Dang CV, (2010) Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression. Proc Natl Acad Sci USA 107, 2037-2042.
16. Salahudeen AK, Clark EC, &, Nath KA, (1991) Hydrogen peroxide-induced renal injury. A protective role for pyruvate in vitro and in vivo. J Clin Invest 88, 1886-1893.
17. Wang T, Marquardt C, &, Foker J, (1976) Aerobic glycolysis during lymphocyte proliferation. Nature 261, 702-705.
18. Karpatkin S, &, Amorosi EL, (1977) Platelet heterogeneity. Br J Haematol 35, 681-684.
19. Pfeiffer T, Schuster S, &, Bonhoeffer S, (2001) Cooperation and competition in the evolution of ATP-producing pathways. Science 292, 504-507. (Pubitemid 32335953)
20. Bulik S, Grimbs S, Huthmacher C, Selbig J, &, Holzhutter HG, (2009) Kinetic hybrid models composed of mechanistic and simplified enzymatic rate laws-a promising method for speeding up the kinetic modelling of complex metabolic networks. FEBS J 276, 410-424.
21. Schuster R, &, Holzhutter HG, (1995) Use of mathematical models for predicting the metabolic effect of large-scale enzyme activity alterations. Application to enzyme deficiencies of red blood cells. Eur J Biochem 229, 403-418.
22. Marin-Hernandez A, Rodriguez-Enriquez S, Vital-Gonzalez PA, Flores-Rodriguez FL, Macias-Silva M, Sosa-Garrocho M, &, Moreno-Sanchez R, (2006) Determining and understanding the control of glycolysis in fast-growth tumor cells. Flux control by an over-expressed but strongly product-inhibited hexokinase. FEBS J 273, 1975-1988.
23. Fell DA, (1992) Metabolic control analysis: a survey of its theoretical and experimental development. Biochem J 286, 313-330.
24. Heinrich R, &, Rapoport TA, (1974) A linear steady-state treatment of enzymatic chains. General properties, control and effector strength. Eur J Biochem 42, 89-95.
25. Kacser H, &, Burns JA, (1973) The control of flux. Symp Soc Exp Biol 27, 65-104.
26. Korzeniewski B, &, Mazat JP, (1996) Theoretical studies on control of oxidative phosphorylation in muscle mitochondria at different energy demands and oxygen concentrations. Acta Biotheor 44, 263-269. (Pubitemid 27025332)
27. Smith TA, (1999) Facilitative glucose transporter expression in human cancer tissue. Br J Biomed Sci 56, 285-292. (Pubitemid 30008823)
28. Medina RA, &, Owen GI, (2002) Glucose transporters: expression, regulation and cancer. Biol Res 35, 9-26. (Pubitemid 34661867)
29. Binder C, Binder L, Marx D, Schauer A, &, Hiddemann W, (1997) Deregulated simultaneous expression of multiple glucose transporter isoforms in malignant cells and tissues. Anticancer Res 17, 4299-4304. (Pubitemid 28081703)
30. Noguchi Y, Yoshikawa T, Marat D, Doi C, Makino T, Fukuzawa K, Tsuburaya A, Satoh S, Ito T, &, Mitsuse S, (1998) Insulin resistance in cancer patients is associated with enhanced tumor necrosis factor-alpha expression in skeletal muscle. Biochem Biophys Res Commun 253, 887-892. (Pubitemid 29039240)
31. Oliver RJ, Woodwards RT, Sloan P, Thakker NS, Stratford IJ, &, Airley RE, (2004) Prognostic value of facilitative glucose transporter Glut-1 in oral squamous cell carcinomas treated by surgical resection; results of EORTC Translational Research Fund studies. Eur J Cancer 40, 503-507. (Pubitemid 38220765)
32. Grover-McKay M, Walsh SA, Seftor EA, Thomas PA, &, Hendrix MJ, (1998) Role for glucose transporter 1 protein in human breast cancer. Pathol Oncol Res 4, 115-120. (Pubitemid 28394627)
33. Tateishi U, Yamaguchi U, Seki K, Terauchi T, Arai Y, &, Hasegawa T, (2006) Glut-1 expression and enhanced glucose metabolism are associated with tumour grade in bone and soft tissue sarcomas: a prospective evaluation by [18F]fluorodeoxyglucose positron emission tomography. Eur J Nucl Med Mol Imaging 33, 683-691. (Pubitemid 43846759)
34. Chen C, Pore N, Behrooz A, Ismail-Beigi F, &, Maity A, (2001) Regulation of glut1 mRNA by hypoxia-inducible factor-1. Interaction between H-ras and hypoxia. J Biol Chem 276, 9519-9525.
35. Osthus RC, Shim H, Kim S, Li Q, Reddy R, Mukherjee M, Xu Y, Wonsey D, Lee LA, &, Dang CV, (2000) Deregulation of glucose transporter 1 and glycolytic gene expression by c-Myc. J Biol Chem 275, 21797-21800. (Pubitemid 30621745)
36. Kroemer G, &, Pouyssegur J, (2008) Tumor cell metabolism: cancer's Achilles' heel. Cancer Cell 13, 472-482. (Pubitemid 351766797)
37. Rathmell JC, Fox CJ, Plas DR, Hammerman PS, Cinalli RM, &, Thompson CB, (2003) Akt-directed glucose metabolism can prevent Bax conformation change and promote growth factor-independent survival. Mol Cell Biol 23, 7315-7328. (Pubitemid 37211011)
38. Zelzer E, Levy Y, Kahana C, Shilo BZ, Rubinstein M, &, Cohen B, (1998) Insulin induces transcription of target genes through the hypoxia-inducible factor HIF-1alpha/ARNT. EMBO J 17, 5085-5094. (Pubitemid 28408474)
39. Behrooz A, &, Ismail-Beigi F, (1999) Stimulation of glucose transport by hypoxia: signals and mechanisms. News Physiol Sci 14, 105-110.
40. Zhang JZ, Behrooz A, &, Ismail-Beigi F, (1999) Regulation of glucose transport by hypoxia. Am J Kidney Dis 34, 189-202. (Pubitemid 29318818)
41. Hamilton BJ, Nichols RC, Tsukamoto H, Boado RJ, Pardridge WM, &, Rigby WF, (1999) hnRNP A2 and hnRNP L bind the 3′UTR of glucose transporter 1 mRNA and exist as a complex in vivo. Biochem Biophys Res Commun 261, 646-651. (Pubitemid 29408112)
42. Ganapathy V, Thangaraju M, &, Prasad PD, (2009) Nutrient transporters in cancer: relevance to Warburg hypothesis and beyond. Pharmacol Ther 121, 29-40.
43. Weihua Z, Tsan R, Huang WC, Wu Q, Chiu CH, Fidler IJ, &, Hung MC, (2008) Survival of cancer cells is maintained by EGFR independent of its kinase activity. Cancer Cell 13, 385-393. (Pubitemid 351609444)
44. Rodriguez-Enriquez S, Marin-Hernandez A, Gallardo-Perez JC, &, Moreno-Sanchez R, (2009) Kinetics of transport and phosphorylation of glucose in cancer cells. J Cell Physiol 221, 552-559.
45. Scheepers A, Joost HG, &, Schurmann A, (2004) The glucose transporter families SGLT and GLUT: molecular basis of normal and aberrant function. JPEN J Parenter Enteral Nutr 28, 364-371. (Pubitemid 39121460)
46. Mathupala SP, Ko YH, &, Pedersen PL, (2009) Hexokinase-2 bound to mitochondria: cancer's stygian link to the 'Warburg effect' and a pivotal target for effective therapy. Semin Cancer Biol 19, 17-24.
47. Johansson T, Berrez JM, &, Nelson BD, (1985) Evidence that transcription of the hexokinase gene is increased in a rapidly growing rat hepatoma. Biochem Biophys Res Commun 133, 608-613. (Pubitemid 16103891)
48. Mathupala SP, Rempel A, &, Pedersen PL, (1995) Glucose catabolism in cancer cells. Isolation, sequence, and activity of the promoter for type II hexokinase. J Biol Chem 270, 16918-16925.
49. Rempel A, Bannasch P, &, Mayer D, (1994) Differences in expression and intracellular distribution of hexokinase isoenzymes in rat liver cells of different transformation stages. Biochim Biophys Acta 1219, 660-668. (Pubitemid 24353384)
50. Rempel A, Bannasch P, &, Mayer D, (1994) Microheterogeneity of cytosolic and membrane-bound hexokinase II in Morris hepatoma 3924A. Biochem J 303, 269-274. (Pubitemid 24302929)
51. Wolf A, Agnihotri S, Micallef J, Mukherjee J, Sabha N, Cairns R, Hawkins C, &, Guha A, (2011) Hexokinase 2 is a key mediator of aerobic glycolysis and promotes tumor growth in human glioblastoma multiforme. J Exp Med 208, 313-326.
52. Wilson JE, (1995) Hexokinases. Rev Physiol Biochem Pharmacol 126, 65-198.
53. Sebastian S, Horton JD, &, Wilson JE, (2000) Anabolic function of the type II isozyme of hexokinase in hepatic lipid synthesis. Biochem Biophys Res Commun 270, 886-891. (Pubitemid 30444801)
54. Pastorino JG, Shulga N, &, Hoek JB, (2002) Mitochondrial binding of hexokinase II inhibits Bax-induced cytochrome c release and apoptosis. J Biol Chem 277, 7610-7618. (Pubitemid 34953160)
55. Arora KK, &, Pedersen PL, (1988) Functional significance of mitochondrial bound hexokinase in tumor cell metabolism. Evidence for preferential phosphorylation of glucose by intramitochondrially generated ATP. J Biol Chem 263, 17422-17428. (Pubitemid 19029327)
56. Bessman SP, &, Fonyo A, (1966) The possible role of the mitochondrial bound creatine kinase in regulation of mitochondrial respiration. Biochem Biophys Res Commun 22, 597-602.
57. Nelson BD, &, Kabir F, (1985) Adenylate kinase is a source of ATP for tumor mitochondrial hexokinase. Biochim Biophys Acta 841, 195-200. (Pubitemid 15240497)
58. Marie C, &, Bralet J, (1991) Blood glucose level and morphological brain damage following cerebral ischemia. Cerebrovasc Brain Metab Rev 3, 29-38.
59. Baines CP, Kaiser RA, Sheiko T, Craigen WJ, &, Molkentin JD, (2007) Voltage-dependent anion channels are dispensable for mitochondrial-dependent cell death. Nat Cell Biol 9, 550-555. (Pubitemid 46696536)
60. Yanagawa T, Funasaka T, Tsutsumi S, Raz T, Tanaka N, &, Raz A, (2005) Differential regulation of phosphoglucose isomerase/autocrine motility factor activities by protein kinase CK2 phosphorylation. J Biol Chem 280, 10419-10426. (Pubitemid 40395899)
61. Funasaka T, Yanagawa T, Hogan V, &, Raz A, (2005) Regulation of phosphoglucose isomerase/autocrine motility factor expression by hypoxia. FASEB J 19, 1422-1430. (Pubitemid 41279000)
62. Liotta LA, Guirguis RA, &, Schiffmann E, (1986) Tumor autocrine motility factor. Prog Clin Biol Res 212, 17-24.
63. Yanagawa T, Watanabe H, Takeuchi T, Fujimoto S, Kurihara H, &, Takagishi K, (2004) Overexpression of autocrine motility factor in metastatic tumor cells: possible association with augmented expression of KIF3A and GDI-beta. Lab Invest 84, 513-522. (Pubitemid 41656479)
64. Haga A, Niinaka Y, &, Raz A, (2000) Phosphohexose isomerase/autocrine motility factor/neuroleukin/maturation factor is a multifunctional phosphoprotein. Biochim Biophys Acta 1480, 235-244. (Pubitemid 30427401)
65. Davies SE, &, Brindle KM, (1992) Effects of overexpression of phosphofructokinase on glycolysis in the yeast Saccharomyces cerevisiae. Biochemistry 31, 4729-4735.
66. Clem B, Telang S, Clem A, Yalcin A, Meier J, Simmons A, Rasku MA, Arumugam S, Dean WL, Eaton J, et al. (2008) Small-molecule inhibition of 6-phosphofructo-2-kinase activity suppresses glycolytic flux and tumor growth. Mol Cancer Ther 7, 110-120.
67. Meldolesi MF, Macchia V, &, Laccetti P, (1976) Differences in phosphofructokinase regulation in normal and tumor rat thyroid cells. J Biol Chem 251, 6244-6251.
68. Randle PJ, Garland PB, Hales CN, &, Newsholme EA, (1963) The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1, 785-789.
69. Ravussin E, Bogardus C, Scheidegger K, LaGrange B, Horton ED, &, Horton ES, (1986) Effect of elevated FFA on carbohydrate and lipid oxidation during prolonged exercise in humans. J Appl Physiol 60, 893-900. (Pubitemid 16013253)
70. Wenzel KW, Kurganov BI, Zimmermann G, Yakovlev VA, Schellenberger W, &, Hofmann E, (1976) Self-association of human erythrocyte phosphofructokinase. Kinetic behaviour in dependence on enzyme concentration and mode of association. Eur J Biochem 61, 181-190.
71. 2+-induced changes in energy metabolism and viability of melanoma cells. Br J Cancer 81, 219-224. (Pubitemid 29423698)
72. Yalcin A, Telang S, Clem B, &, Chesney J, (2009) Regulation of glucose metabolism by 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatases in cancer. Exp Mol Pathol 86, 174-179.
73. Minchenko A, Leshchinsky I, Opentanova I, Sang N, Srinivas V, Armstead V, &, Caro J, (2002) Hypoxia-inducible factor-1-mediated expression of the 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 (PFKFB3) gene. J Biol Chem 277, 6183-6187. (Pubitemid 34968408)
74. Atsumi T, Chesney J, Metz C, Leng L, Donnelly S, Makita Z, Mitchell R, &, Bucala R, (2002) High expression of inducible 6-phosphofructo-2-kinase/ fructose-2,6-bisphosphatase (iPFK-2; PFKFB3) in human cancers. Cancer Res 62, 5881-5887. (Pubitemid 35204749)
75. Yun H, Lee M, Kim SS, &, Ha J, (2005) Glucose deprivation increases mRNA stability of vascular endothelial growth factor through activation of AMP-activated protein kinase in DU145 prostate carcinoma. J Biol Chem 280, 9963-9972. (Pubitemid 40395845)
76. Shaw RJ, &, Cantley LC, (2006) Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 441, 424-430. (Pubitemid 44050136)
77. Wang XT, &, Engel PC, (2009) Clinical mutants of human glucose 6-phosphate dehydrogenase: impairment of NADP(+) binding affects both folding and stability. Biochim Biophys Acta 1792, 804-809.
78. de Haan JH, Klomp DW, Tack CJ, &, Heerschap A, (2003) Optimized detection of changes in glucose-6-phosphate levels in human skeletal muscle by 31P MR spectroscopy. Magn Reson Med 50, 1302-1306. (Pubitemid 37494032)
79. Schuster R, Jacobasch G, &, Holzhutter H, (1990) Mathematical modelling of energy and redox metabolism of G6PD-deficient erythrocytes. Biomed Biochim Acta 49, S160-165. (Pubitemid 20300769)
80. Bensaad K, Tsuruta A, Selak MA, Vidal MN, Nakano K, Bartrons R, Gottlieb E, &, Vousden KH, (2006) TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell 126, 107-120. (Pubitemid 44040989)
81. Li H, &, Jogl G, (2009) Structural and biochemical studies of TIGAR (TP53-induced glycolysis and apoptosis regulator). J Biol Chem 284, 1748-1754.
82. Kumanishi T, Ikuta F, &, Yamamoto T, (1970) Aldolase isozyme patterns of representative tumours in the human nervous system. Acta Neuropathol 16, 220-225.
83. Marin-Hernandez A, Gallardo-Perez JC, Ralph SJ, Rodriguez-Enriquez S, &, Moreno-Sanchez R, (2009) HIF-1alpha modulates energy metabolism in cancer cells by inducing over-expression of specific glycolytic isoforms. Mini Rev Med Chem 9, 1084-1101.
84. Lu H, Forbes RA, &, Verma A, (2002) Hypoxia-inducible factor 1 activation by aerobic glycolysis implicates the Warburg effect in carcinogenesis. J Biol Chem 277, 23111-23115. (Pubitemid 34952134)
85. Choi HJ, Eun JS, Kim DK, Li RH, Shin TY, Park H, Cho NP, &, Soh Y, (2008) Icariside II from Epimedium koreanum inhibits hypoxia-inducible factor-1alpha in human osteosarcoma cells. Eur J Pharmacol 579, 58-65.
86. Khalil AA, (2007) Biomarker discovery: a proteomic approach for brain cancer profiling. Cancer Sci 98, 201-213. (Pubitemid 44941872)
87. Peng SY, Lai PL, Pan HW, Hsiao LP, &, Hsu HC, (2008) Aberrant expression of the glycolytic enzymes aldolase B and type II hexokinase in hepatocellular carcinoma are predictive markers for advanced stage, early recurrence and poor prognosis. Oncol Rep 19, 1045-1053.
88. Song H, Xia SL, Liao C, Li YL, Wang YF, Li TP, &, Zhao MJ, (2004) Genes encoding Pir51, Beclin 1, RbAp48 and aldolase b are up or down-regulated in human primary hepatocellular carcinoma. World J Gastroenterol 10, 509-513. (Pubitemid 38325305)
89. Cui Y, Tian M, Zong M, Teng M, Chen Y, Lu J, Jiang J, Liu X, &, Han J, (2009) Proteomic analysis of pancreatic ductal adenocarcinoma compared with normal adjacent pancreatic tissue and pancreatic benign cystadenoma. Pancreatology 9, 89-98.
90. van den Bemd GJ, Krijgsveld J, Luider TM, van Rijswijk AL, Demmers JA, &, Jenster G, (2006) Mass spectrometric identification of human prostate cancer-derived proteins in serum of xenograft-bearing mice. Mol Cell Proteomics 5, 1830-1839. (Pubitemid 44688192)
91. Taguchi K, &, Takagi Y, (2001) [Aldolase]. Rinsho Byori 116 (Suppl), 117-124.
92. Ochi Y, Okabe H, Inui T, &, Yamashiro K, (1997) [Tumor marker-present and future]. Rinsho Byori 45, 875-883.
93. Jang M, Kang HJ, Lee SY, Chung SJ, Kang S, Chi SW, Cho S, Lee SC, Lee CK, Park BC, et al. (2009) Glyceraldehyde-3-phosphate, a glycolytic intermediate, plays a key role in controlling cell fate via inhibition of caspase activity. Mol Cells 28, 559-563.
94. Estival A, Durand S, Clerc P, Louvel D, Vaysse N, Valdiguie P, &, Clemente F, (1997) Pancreatic cancer cell regulation by lipids and by basic fibroblast growth factor expression. Cancer Detect Prev 21, 546-552. (Pubitemid 27518943)
95. Robert J, Van Rymenant M, &, Lagae F, (1961) Enzymes in cancer. III. Triosephosphate isomerase activity of human blood serum in normal individuals and in individuals with various pathological conditions. Cancer 14, 1166-1174.
96. Tamesa MS, Kuramitsu Y, Fujimoto M, Maeda N, Nagashima Y, Tanaka T, Yamamoto S, Oka M, &, Nakamura K, (2009) Detection of autoantibodies against cyclophilin A and triosephosphate isomerase in sera from breast cancer patients by proteomic analysis. Electrophoresis 30, 2168-2181.
97. Wang X, Lu Y, Yang J, Shi Y, Lan M, Liu Z, Zhai H, &, Fan D, (2008) Identification of triosephosphate isomerase as an anti-drug resistance agent in human gastric cancer cells using functional proteomic analysis. J Cancer Res Clin Oncol 134, 995-1003.
98. Colell A, Green DR, &, Ricci JE, (2009) Novel roles for GAPDH in cell death and carcinogenesis. Cell Death Differ 16, 1573-1581.
99. Semenza GL, (2000) HIF-1: mediator of physiological and pathophysiological responses to hypoxia. J Appl Physiol 88, 1474-1480. (Pubitemid 30217451)
100. Colell A, Ricci JE, Tait S, Milasta S, Maurer U, Bouchier-Hayes L, Fitzgerald P, Guio-Carrion A, Waterhouse NJ, Li CW, et al. (2007) GAPDH and autophagy preserve survival after apoptotic cytochrome c release in the absence of caspase activation. Cell 129, 983-997. (Pubitemid 46813151)
101. Tarze A, Deniaud A, Le Bras M, Maillier E, Molle D, Larochette N, Zamzami N, Jan G, Kroemer G, &, Brenner C, (2007) GAPDH, a novel regulator of the pro-apoptotic mitochondrial membrane permeabilization. Oncogene 26, 2606-2620. (Pubitemid 46632015)
102. Hwang TL, Liang Y, Chien KY, &, Yu JS, (2006) Overexpression and elevated serum levels of phosphoglycerate kinase 1 in pancreatic ductal adenocarcinoma. Proteomics 6, 2259-2272.
103. Lay AJ, Jiang XM, Kisker O, Flynn E, Underwood A, Condron R, &, Hogg PJ, (2000) Phosphoglycerate kinase acts in tumour angiogenesis as a disulphide reductase. Nature 408, 869-873. (Pubitemid 32016098)
104. Daly EB, Wind T, Jiang XM, Sun L, &, Hogg PJ, (2004) Secretion of phosphoglycerate kinase from tumour cells is controlled by oxygen-sensing hydroxylases. Biochim Biophys Acta 1691, 17-22. (Pubitemid 38410946)
105. Durany N, Joseph J, Campo E, Molina R, &, Carreras J, (1997) Phosphoglycerate mutase, 2,3-bisphosphoglycerate phosphatase and enolase activity and isoenzymes in lung, colon and liver carcinomas. Br J Cancer 75, 969-977. (Pubitemid 27122614)
106. Durany N, Joseph J, Jimenez OM, Climent F, Fernandez PL, Rivera F, &, Carreras J, (2000) Phosphoglycerate mutase, 2,3-bisphosphoglycerate phosphatase, creatine kinase and enolase activity and isoenzymes in breast carcinoma. Br J Cancer 82, 20-27. (Pubitemid 30008953)
107. Kondoh H, Lleonart ME, Gil J, Wang J, Degan P, Peters G, Martinez D, Carnero A, &, Beach D, (2005) Glycolytic enzymes can modulate cellular life span. Cancer Res 65, 177-185. (Pubitemid 40070808)
108. Sedoris KC, Thomas SD, &, Miller DM, (2010) Hypoxia induces differential translation of enolase/MBP-1. BMC Cancer 10, 157.
109. Christofk HR, Vander Heiden MG, Harris MH, Ramanathan A, Gerszten RE, Wei R, Fleming MD, Schreiber SL, &, Cantley LC, (2008) The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 452, 230-233. (Pubitemid 351380249)
110. Hacker HJ, Steinberg P, &, Bannasch P, (1998) Pyruvate kinase isoenzyme shift from L-type to M2-type is a late event in hepatocarcinogenesis induced in rats by a choline-deficient/DL-ethionine-supplemented diet. Carcinogenesis 19, 99-107. (Pubitemid 28376831)
111. Christofk HR, Vander Heiden MG, Wu N, Asara JM, &, Cantley LC, (2008) Pyruvate kinase M2 is a phosphotyrosine-binding protein. Nature 452, 181-186. (Pubitemid 351380242)
112. Vander Heiden MG, Cantley LC, &, Thompson CB, (2009) Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324, 1029-1033.
113. Mazurek S, (2010) Pyruvate kinase type M2: a key regulator of the metabolic budget system in tumor cells. Int J Biochem Cell Biol, doi:.
114. Kress S, Stein A, Maurer P, Weber B, Reichert J, Buchmann A, Huppert P, &, Schwarz M, (1998) Expression of hypoxia-inducible genes in tumor cells. J Cancer Res Clin Oncol 124, 315-320. (Pubitemid 28332913)
115. Discher DJ, Bishopric NH, Wu X, Peterson CA, &, Webster KA, (1998) Hypoxia regulates beta-enolase and pyruvate kinase-M promoters by modulating Sp1/Sp3 binding to a conserved GC element. J Biol Chem 273, 26087-26093. (Pubitemid 28475843)
116. Yamada K, &, Noguchi T, (1999) Regulation of pyruvate kinase M gene expression. Biochem Biophys Res Commun 256, 257-262. (Pubitemid 29298870)
117. Halestrap AP, &, Price NT, (1999) The proton-linked monocarboxylate transporter (MCT) family: structure, function and regulation. Biochem J 343, 281-299. (Pubitemid 29511759)
118. Gallagher SM, Castorino JJ, Wang D, &, Philp NJ, (2007) Monocarboxylate transporter 4 regulates maturation and trafficking of CD147 to the plasma membrane in the metastatic breast cancer cell line MDA-MB-231. Cancer Res 67, 4182-4189. (Pubitemid 46815064)
119. Pinheiro C, Longatto-Filho A, Scapulatempo C, Ferreira L, Martins S, Pellerin L, Rodrigues M, Alves VA, Schmitt F, &, Baltazar F, (2008) Increased expression of monocarboxylate transporters 1, 2, and 4 in colorectal carcinomas. Virchows Arch 452, 139-146.
120. Koukourakis MI, Giatromanolaki A, Polychronidis A, Simopoulos C, Gatter KC, Harris AL, &, Sivridis E, (2006) Endogenous markers of hypoxia/anaerobic metabolism and anemia in primary colorectal cancer. Cancer Sci 97, 582-588. (Pubitemid 44056605)
121. Lambert DW, Wood IS, Ellis A, &, Shirazi-Beechey SP, (2002) Molecular changes in the expression of human colonic nutrient transporters during the transition from normality to malignancy. Br J Cancer 86, 1262-1269.
122. Pinheiro C, Albergaria A, Paredes J, Sousa B, Dufloth R, Vieira D, Schmitt F, &, Baltazar F, (2010) Monocarboxylate transporter 1 is up-regulated in basal-like breast carcinoma. Histopathology 56, 860-867.
123. Ritzhaupt A, Wood IS, Ellis A, Hosie KB, &, Shirazi-Beechey SP, (1998) Identification and characterization of a monocarboxylate transporter (MCT1) in pig and human colon: its potential to transport L-lactate as well as butyrate. J Physiol 513, 719-732. (Pubitemid 29008104)
124. Li H, Myeroff L, Smiraglia D, Romero MF, Pretlow TP, Kasturi L, Lutterbaugh J, Rerko RM, Casey G, Issa JP, et al. (2003) SLC5A8, a sodium transporter, is a tumor suppressor gene silenced by methylation in human colon aberrant crypt foci and cancers. Proc Natl Acad Sci USA 100, 8412-8417. (Pubitemid 36842559)
125. Paroder V, Spencer SR, Paroder M, Arango D, Schwartz S Jr, Mariadason JM, Augenlicht LH, Eskandari S, &, Carrasco N, (2006) Na(+)/monocarboxylate transport (SMCT) protein expression correlates with survival in colon cancer: molecular characterization of SMCT. Proc Natl Acad Sci USA 103, 7270-7275. (Pubitemid 43727822)
126. Hu S, Liu D, Tufano RP, Carson KA, Rosenbaum E, Cohen Y, Holt EH, Kiseljak-Vassiliades K, Rhoden KJ, Tolaney S, et al. (2006) Association of aberrant methylation of tumor suppressor genes with tumor aggressiveness and BRAF mutation in papillary thyroid cancer. Int J Cancer 119, 2322-2329. (Pubitemid 44546951)
127. Porra V, Ferraro-Peyret C, Durand C, Selmi-Ruby S, Giroud H, Berger-Dutrieux N, Decaussin M, Peix JL, Bournaud C, Orgiazzi J, et al. (2005) Silencing of the tumor suppressor gene SLC5A8 is associated with BRAF mutations in classical papillary thyroid carcinomas. J Clin Endocrinol Metab 90, 3028-3035. (Pubitemid 40686360)
128. Ueno M, Toyota M, Akino K, Suzuki H, Kusano M, Satoh A, Mita H, Sasaki Y, Nojima M, Yanagihara K, et al. (2004) Aberrant methylation and histone deacetylation associated with silencing of SLC5A8 in gastric cancer. Tumour Biol 25, 134-140. (Pubitemid 39274282)
129. Hong C, Maunakea A, Jun P, Bollen AW, Hodgson JG, Goldenberg DD, Weiss WA, &, Costello JF, (2005) Shared epigenetic mechanisms in human and mouse gliomas inactivate expression of the growth suppressor SLC5A8. Cancer Res 65, 3617-3623. (Pubitemid 40616338)
130. Park JY, Zheng W, Kim D, Cheng JQ, Kumar N, Ahmad N, &, Pow-Sang J, (2007) Candidate tumor suppressor gene SLC5A8 is frequently down-regulated by promoter hypermethylation in prostate tumor. Cancer Detect Prev 31, 359-365. (Pubitemid 350166790)
131. Park JY, Helm JF, Zheng W, Ly QP, Hodul PJ, Centeno BA, &, Malafa MP, (2008) Silencing of the candidate tumor suppressor gene solute carrier family 5 member 8 (SLC5A8) in human pancreatic cancer. Pancreas 36, e32-39. (Pubitemid 351591592)
132. Eboli ML, Paradies G, Galeotti T, &, Papa S, (1977) Pyruvate transport in tumour-cell mitochondria. Biochim Biophys Acta 460, 183-187.
133. Paradies G, Capuano F, Palombini G, Galeotti T, &, Papa S, (1983) Transport of pyruvate in mitochondria from different tumor cells. Cancer Res 43, 5068-5071. (Pubitemid 14227478)
134. Kim JW, Tchernyshyov I, Semenza GL, &, Dang CV, (2006) HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab 3, 177-185.
135. Papandreou I, Cairns RA, Fontana L, Lim AL, &, Denko NC, (2006) HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption. Cell Metab 3, 187-197.
136. Dietzen DJ, &, Davis EJ, (1993) Oxidation of pyruvate, malate, citrate, and cytosolic reducing equivalents by AS-30D hepatoma mitochondria. Arch Biochem Biophys 305, 91-102. (Pubitemid 23241998)
137. Bayley JP, Kunst HP, Cascon A, Sampietro ML, Gaal J, Korpershoek E, Hinojar-Gutierrez A, Timmers HJ, Hoefsloot LH, Hermsen MA, et al. (2010) SDHAF2 mutations in familial and sporadic paraganglioma and phaeochromocytoma. Lancet Oncol 11, 366-372.
138. Briere JJ, Favier J, Gimenez-Roqueplo AP, &, Rustin P, (2006) Tricarboxylic acid cycle dysfunction as a cause of human diseases and tumor formation. Am J Physiol Cell Physiol 291, C1114-1120. (Pubitemid 44878582)
139. Pollard PJ, Wortham NC, &, Tomlinson IP, (2003) The TCA cycle and tumorigenesis: the examples of fumarate hydratase and succinate dehydrogenase. Ann Med 35, 632-639. (Pubitemid 38005318)
140. Hao HX, Khalimonchuk O, Schraders M, Dephoure N, Bayley JP, Kunst H, Devilee P, Cremers CW, Schiffman JD, Bentz BG, et al. (2009) SDH5, a gene required for flavination of succinate dehydrogenase, is mutated in paraganglioma. Science 325, 1139-1142.
141. Selak MA, Armour SM, MacKenzie ED, Boulahbel H, Watson DG, Mansfield KD, Pan Y, Simon MC, Thompson CB, &, Gottlieb E, (2005) Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. Cancer Cell 7, 77-85. (Pubitemid 40126384)
142. Astuti D, Latif F, Dallol A, Dahia PL, Douglas F, George E, Skoldberg F, Husebye ES, Eng C, &, Maher ER, (2001) Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma. Am J Hum Genet 69, 49-54. (Pubitemid 32614017)
143. Niemann S, &, Muller U, (2000) Mutations in SDHC cause autosomal dominant paraganglioma, type 3. Nat Genet 26, 268-270.
144. Tomlinson IP, Alam NA, Rowan AJ, Barclay E, Jaeger EE, Kelsell D, Leigh I, Gorman P, Lamlum H, Rahman S, et al. (2002) Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nat Genet 30, 406-410.
145. Launonen V, Vierimaa O, Kiuru M, Isola J, Roth S, Pukkala E, Sistonen P, Herva R, &, Aaltonen LA, (2001) Inherited susceptibility to uterine leiomyomas and renal cell cancer. Proc Natl Acad Sci USA 98, 3387-3392. (Pubitemid 32220855)
146. Baysal BE, Ferrell RE, Willett-Brozick JE, Lawrence EC, Myssiorek D, Bosch A, van der Mey A, Taschner PE, Rubinstein WS, Myers EN, et al. (2000) Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science 287, 848-851. (Pubitemid 30084326)
147. Albayrak T, Scherhammer V, Schoenfeld N, Braziulis E, Mund T, Bauer MK, Scheffler IE, &, Grimm S, (2003) The tumor suppressor cybL, a component of the respiratory chain, mediates apoptosis induction. Mol Biol Cell 14, 3082-3096. (Pubitemid 37013112)
148. Ishii T, Yasuda K, Akatsuka A, Hino O, Hartman PS, &, Ishii N, (2005) A mutation in the SDHC gene of complex II increases oxidative stress, resulting in apoptosis and tumorigenesis. Cancer Res 65, 203-209. (Pubitemid 40070811)
149. Chandel NS, McClintock DS, Feliciano CE, Wood TM, Melendez JA, Rodriguez AM, &, Schumacker PT, (2000) Reactive oxygen species generated at mitochondrial complex III stabilize hypoxia-inducible factor-1alpha during hypoxia: a mechanism of O2 sensing. J Biol Chem 275, 25130-25138.
150. Moeller BJ, &, Dewhirst MW, (2004) Raising the bar: how HIF-1 helps determine tumor radiosensitivity. Cell Cycle 3, 1107-1110. (Pubitemid 40268623)
151. Gottlieb E, &, Tomlinson IP, (2005) Mitochondrial tumour suppressors: a genetic and biochemical update. Nat Rev Cancer 5, 857-866. (Pubitemid 41746030)
152. Pollard PJ, Briere JJ, Alam NA, Barwell J, Barclay E, Wortham NC, Hunt T, Mitchell M, Olpin S, Moat SJ, et al. (2005) Accumulation of Krebs cycle intermediates and over-expression of HIF1alpha in tumours which result from germline FH and SDH mutations. Hum Mol Genet 14, 2231-2239. (Pubitemid 41418022)
153. Isaacs JS, Jung YJ, Mole DR, Lee S, Torres-Cabala C, Chung YL, Merino M, Trepel J, Zbar B, Toro J, et al. (2005) HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability. Cancer Cell 8, 143-153. (Pubitemid 41132743)
154. Reitman ZJ, &, Yan H, (2010) Isocitrate dehydrogenase 1 and 2 mutations in cancer: alterations at a crossroads of cellular metabolism. J Natl Cancer Inst 102, 932-941.
155. Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM, Fantin VR, Jang HG, Jin S, Keenan MC, et al. (2009) Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 462, 739-744.
156. Aghili M, Zahedi F, &, Rafiee E, (2009) Hydroxyglutaric aciduria and malignant brain tumor: a case report and literature review. J Neurooncol 91, 233-236.
157. Dajani RM, Danielski J, Gamble W, &, Orten JM, (1961) A study of the citric acid cycle in certain tumour tissue. Biochem J 81, 494-503.
158. Solaini G, Sgarbi G, &, Baracca A, (2011) Oxidative phosphorylation in cancer cells. Biochim Biophys Acta 1807, 534-542.
159. Gogvadze V, Orrenius S, &, Zhivotovsky B, (2008) Mitochondria in cancer cells: what is so special about them? Trends Cell Biol 18, 165-173.
160. Lopez-Rios F, Sanchez-Arago M, Garcia-Garcia E, Ortega AD, Berrendero JR, Pozo-Rodriguez F, Lopez-Encuentra A, Ballestin C, &, Cuezva JM, (2007) Loss of the mitochondrial bioenergetic capacity underlies the glucose avidity of carcinomas. Cancer Res 67, 9013-9017. (Pubitemid 47535883)
161. Ristow M, (2006) Oxidative metabolism in cancer growth. Curr Opin Clin Nutr Metab Care 9, 339-345. (Pubitemid 44097804)
162. Cuezva JM, Krajewska M, de Heredia ML, Krajewski S, Santamaria G, Kim H, Zapata JM, Marusawa H, Chamorro M, &, Reed JC, (2002) The bioenergetic signature of cancer: a marker of tumor progression. Cancer Res 62, 6674-6681. (Pubitemid 35364137)
163. Isidoro A, Martinez M, Fernandez PL, Ortega AD, Santamaria G, Chamorro M, Reed JC, &, Cuezva JM, (2004) Alteration of the bioenergetic phenotype of mitochondria is a hallmark of breast, gastric, lung and oesophageal cancer. Biochem J 378, 17-20. (Pubitemid 38299539)
164. Isidoro A, Casado E, Redondo A, Acebo P, Espinosa E, Alonso AM, Cejas P, Hardisson D, Fresno Vara JA, Belda-Iniesta C, et al. (2005) Breast carcinomas fulfill the Warburg hypothesis and provide metabolic markers of cancer prognosis. Carcinogenesis 26, 2095-2104. (Pubitemid 41672197)
165. Thierbach R, Schulz TJ, Isken F, Voigt A, Mietzner B, Drewes G, von Kleist-Retzow JC, Wiesner RJ, Magnuson MA, Puccio H, et al. (2005) Targeted disruption of hepatic frataxin expression causes impaired mitochondrial function, decreased life span and tumor growth in mice. Hum Mol Genet 14, 3857-3864. (Pubitemid 43020087)
166. Simonnet H, Demont J, Pfeiffer K, Guenaneche L, Bouvier R, Brandt U, Schagger H, &, Godinot C, (2003) Mitochondrial complex I is deficient in renal oncocytomas. Carcinogenesis 24, 1461-1466. (Pubitemid 37160836)
167. Matoba S, Kang JG, Patino WD, Wragg A, Boehm M, Gavrilova O, Hurley PJ, Bunz F, &, Hwang PM, (2006) p53 regulates mitochondrial respiration. Science 312, 1650-1653. (Pubitemid 43902663)
168. Fukuda R, Zhang H, Kim JW, Shimoda L, Dang CV, &, Semenza GL, (2007) HIF-1 regulates cytochrome oxidase subunits to optimize efficiency of respiration in hypoxic cells. Cell 129, 111-122. (Pubitemid 46507584)
169. Palmieri F, Quagliariello E, &, Klingenberger M, (1972) Kinetics and specificity of the oxoglutarate carrier in rat-liver mitochondria. Eur J Biochem 29, 408-416.
170. Parlo RA, &, Coleman PS, (1984) Enhanced rate of citrate export from cholesterol-rich hepatoma mitochondria. The truncated Krebs cycle and other metabolic ramifications of mitochondrial membrane cholesterol. J Biol Chem 259, 9997-10003. (Pubitemid 14067666)
171. Parlo RA, &, Coleman PS, (1986) Continuous pyruvate carbon flux to newly synthesized cholesterol and the suppressed evolution of pyruvate-generated CO2 in tumors: further evidence for a persistent truncated Krebs cycle in hepatomas. Biochim Biophys Acta 886, 169-176. (Pubitemid 16024076)
172. Hatzivassiliou G, Zhao F, Bauer DE, Andreadis C, Shaw AN, Dhanak D, Hingorani SR, Tuveson DA, &, Thompson CB, (2005) ATP citrate lyase inhibition can suppress tumor cell growth. Cancer Cell 8, 311-321. (Pubitemid 41443416)
173. Berwick DC, Hers I, Heesom KJ, Moule SK, &, Tavare JM, (2002) The identification of ATP-citrate lyase as a protein kinase B (Akt) substrate in primary adipocytes. J Biol Chem 277, 33895-33900.
174. Kuhajda FP, (2000) Fatty-acid synthase and human cancer: new perspectives on its role in tumor biology. Nutrition 16, 202-208. (Pubitemid 30114274)
175. Yoon S, Lee MY, Park SW, Moon JS, Koh YK, Ahn YH, Park BW, &, Kim KS, (2007) Up-regulation of acetyl-CoA carboxylase alpha and fatty acid synthase by human epidermal growth factor receptor 2 at the translational level in breast cancer cells. J Biol Chem 282, 26122-26131. (Pubitemid 47443806)
176. Graner E, Tang D, Rossi S, Baron A, Migita T, Weinstein LJ, Lechpammer M, Huesken D, Zimmermann J, Signoretti S, et al. (2004) The isopeptidase USP2a regulates the stability of fatty acid synthase in prostate cancer. Cancer Cell 5, 253-261. (Pubitemid 38402117)
177. Shah US, Dhir R, Gollin SM, Chandran UR, Lewis D, Acquafondata M, &, Pflug BR, (2006) Fatty acid synthase gene overexpression and copy number gain in prostate adenocarcinoma. Hum Pathol 37, 401-409.
178. Mashima T, Seimiya H, &, Tsuruo T, (2009) De novo fatty-acid synthesis and related pathways as molecular targets for cancer therapy. Br J Cancer 100, 1369-1372.
179. Boxer GE, &, Shonk CE, (1960) Low levels of soluble DPN-linked alpha-glycerophosphate dehydrogenase in tumors. Cancer Res 20, 85-91.
180. Pollock RJ, Hajra AK, &, Agranoff BW, (1975) The relative utilization of the acyl dihydroxyacetone phosphate and glycerol phosphate pathways for synthesis of glycerolipids in various tumors and normal tissues. Biochim Biophys Acta 380, 421-435.
181. Yano K, Ohoshima S, Shimizu Y, Moriguchi T, &, Katayama H, (1996) Evaluation of glycogen level in human lung carcinoma tissues by an infrared spectroscopic method. Cancer Lett 110, 29-34. (Pubitemid 27047562)
182. Wong PT, Wong RK, Caputo TA, Godwin TA, &, Rigas B, (1991) Infrared spectroscopy of exfoliated human cervical cells: evidence of extensive structural changes during carcinogenesis. Proc Natl Acad Sci USA 88, 10988-10992. (Pubitemid 21915964)
183. Rigas B, Morgello S, Goldman IS, &, Wong PT, (1990) Human colorectal cancers display abnormal Fourier-transform infrared spectra. Proc Natl Acad Sci USA 87, 8140-8144.
184. Rousset M, Paris H, Chevalier G, Terrain B, Murat JC, &, Zweibaum A, (1984) Growth-related enzymatic control of glycogen metabolism in cultured human tumor cells. Cancer Res 44, 154-160. (Pubitemid 14178078)
185. Nigam VN, Macdonald HL, &, Cantero A, (1962) Limiting factors for glycogen storage in tumors. I. Limiting enzymes. Cancer Res 22, 131-138.
186. Gururaj A, Barnes CJ, Vadlamudi RK, &, Kumar R, (2004) Regulation of phosphoglucomutase 1 phosphorylation and activity by a signaling kinase. Oncogene 23, 8118-8127. (Pubitemid 39531852)
187. Lowry OH, &, Passonneau JV, (1969) Phosphoglucomutase kinetics with the phosphates of fructose, glucose, mannose, ribose, and galactose. J Biol Chem 244, 910-916.
188. Kim J, Kim SH, Lee SU, Ha GH, Kang DG, Ha NY, Ahn JS, Cho HY, Kang SJ, Lee YJ, et al. (2002) Proteome analysis of human liver tumor tissue by two-dimensional gel electrophoresis and matrix assisted laser desorption/ionization-mass spectrometry for identification of disease-related proteins. Electrophoresis 23, 4142-4156. (Pubitemid 36131469)
189. Aiston S, Hampson L, Gomez-Foix AM, Guinovart JJ, &, Agius L, (2001) Hepatic glycogen synthesis is highly sensitive to phosphorylase activity: evidence from metabolic control analysis. J Biol Chem 276, 23858-23866.
190. Shulman RG, Bloch G, &, Rothman DL, (1995) In vivo regulation of muscle glycogen synthase and the control of glycogen synthesis. Proc Natl Acad Sci USA 92, 8535-8542.
191. Villar-Palasi C, &, Guinovart JJ, (1997) The role of glucose 6-phosphate in the control of glycogen synthase. FASEB J 11, 544-558. (Pubitemid 27274428)
192. Luo J, (2009) Glycogen synthase kinase 3beta (GSK3beta) in tumorigenesis and cancer chemotherapy. Cancer Lett 273, 194-200.
193. Rayasam GV, Tulasi VK, Sodhi R, Davis JA, &, Ray A, (2009) Glycogen synthase kinase 3: more than a namesake. Br J Pharmacol 156, 885-898.
194. Zhu Q, Yang J, Han S, Liu J, Holzbeierlein J, Thrasher JB, &, Li B, (2011) Suppression of glycogen synthase kinase 3 activity reduces tumor growth of prostate cancer in vivo. Prostate 71, 835-845.
195. Mishra R, (2010) Glycogen synthase kinase 3 beta: can it be a target for oral cancer. Mol Cancer 9, 144.
196. Luo J, Chen J, Deng ZL, Luo X, Song WX, Sharff KA, Tang N, Haydon RC, Luu HH, &, He TC, (2007) Wnt signaling and human diseases: what are the therapeutic implications? Lab Invest 87, 97-103.
197. Patel S, &, Woodgett J, (2008) Glycogen synthase kinase-3 and cancer: good cop, bad cop? Cancer Cell 14, 351-353.
198. Newgard CB, Hwang PK, &, Fletterick RJ, (1989) The family of glycogen phosphorylases-structure and function. Crit Rev Biochem Mol Biol 24, 69-99.
199. Gelinas RP, Froman BE, McElroy F, Tait RC, &, Gorin FA, (1989) Human brain glycogen phosphorylase: characterization of fetal cDNA and genomic sequences. Brain Res Mol Brain Res 6, 177-185. (Pubitemid 19270019)
200. Hashimoto K, Tamura K, Otani H, &, Tanaka O, (1995) Histocytochemical and immunohistochemical studies related to the role of glycogen in human developing digestive organs. Anat Embryol (Berl) 192, 497-505.
201. Sato K, Morris HP, &, Weinhouse S, (1972) Phosphorylase: a new isozyme in rat hepatic tumors and fetal liver. Science 178, 879-881.
202. Shimada S, Maeno M, Misumi A, Takano S, &, Akagi M, (1987) Antigen reversion of glycogen phosphorylase isoenzyme in carcinoma and proliferative zone of intestinal metaplasia of the human stomach. An immunohistochemical study. Gastroenterology 93, 35-40. (Pubitemid 17084090)
203. Takashi M, Koshikawa T, Kurobe N, &, Kato K, (1989) Elevated concentrations of brain-type glycogen phosphorylase in renal cell carcinoma. Jpn J Cancer Res 80, 975-980. (Pubitemid 20028813)
204. Tashima S, Shimada S, Yamaguchi K, Tsuruta J, &, Ogawa M, (2000) Expression of brain-type glycogen phosphorylase is a potentially novel early biomarker in the carcinogenesis of human colorectal carcinomas. Am J Gastroenterol 95, 255-263. (Pubitemid 30041569)
205. Mayer D, Seelmann-Eggebert G, &, Letsch I, (1992) Glycogen phosphorylase isoenzymes from hepatoma 3924A and from a non-tumorigenic liver cell line. Comparison with the liver and brain enzymes. Biochem J 282, 665-673.
206. Lee MK, Kim JH, Lee CH, Kim JM, Kang CD, Kim YD, Choi KU, Kim HW, Kim JY, Park do Y, et al. (2006) Clinicopathological significance of BGP expression in non-small-cell lung carcinoma: relationship with histological type, microvessel density and patients' survival. Pathology 38, 555-560. (Pubitemid 47215681)
207. Kotonski B, Wilczek J, Madej J, Zarzycki A, &, Hutny J, (2001) Activity of glycogen depolymerizing enzymes in extracts from brain tumor tissue (anaplastic astrocytoma and glioblastoma multiforme). Acta Biochim Pol 48, 1085-1090. (Pubitemid 33602359)
208. Boros LG, Puigjaner J, Cascante M, Lee WN, Brandes JL, Bassilian S, Yusuf FI, Williams RD, Muscarella P, Melvin WS, et al. (1997) Oxythiamine and dehydroepiandrosterone inhibit the nonoxidative synthesis of ribose and tumor cell proliferation. Cancer Res 57, 4242-4248. (Pubitemid 27413432)
209. Langbein S, Zerilli M, Zur Hausen A, Staiger W, Rensch-Boschert K, Lukan N, Popa J, Ternullo MP, Steidler A, Weiss C, et al. (2006) Expression of transketolase TKTL1 predicts colon and urothelial cancer patient survival: Warburg effect reinterpreted. Br J Cancer 94, 578-585. (Pubitemid 43289763)
210. Tian W-N, Braunstein LD, Pang J, Stuhlmeier KM, Xi Q-C, Tian X, &, Stanton RC, (1998) Importance of glucose-6-phosphate dehydrogenase activity for cell growth. J Biol Chem 273, 10609-10617. (Pubitemid 28227673)
211. Weber G, Hager JC, Lui MS, Prajda N, Tzeng DY, Jackson RC, Takeda E, &, Eble JN, (1981) Biochemical programs of slowly and rapidly growing human colon carcinoma xenografts. Cancer Res 41, 854-859. (Pubitemid 11136325)
212. Frederiks WM, Vizan P, Bosch KS, Vreeling-Sindelarova H, Boren J, &, Cascante M, (2008) Elevated activity of the oxidative and non-oxidative pentose phosphate pathway in (pre)neoplastic lesions in rat liver. Int J Exp Pathol 89, 232-240. (Pubitemid 352019178)
213. Kuo W, Lin J, &, Tang TK, (2000) Human glucose-6-phosphate dehydrogenase (G6PD) gene transforms NIH 3T3 cells and induces tumors in nude mice. Int J Cancer 85, 857-864. (Pubitemid 30131478)
214. Li D, Zhu Y, Tang Q, Lu H, Li H, Yang Y, Li Z, &, Tong S, (2009) A new G6PD knockdown tumor-cell line with reduced proliferation and increased susceptibility to oxidative stress. Cancer Biother Radiopharm 24, 81-90.
215. Nordenberg J, Aviram R, Beery E, Stenzel KH, &, Novogrodsky A, (1984) Inhibition of 6-phosphogluconate dehydrogenase by glucose 1,6-diphosphate in human normal and malignant colon extracts. Cancer Lett 23, 193-199. (Pubitemid 14054039)
216. Frederiks WM, Bosch KS, De Jong JS, &, Van Noorden CJ, (2003) Post-translational regulation of glucose-6-phosphate dehydrogenase activity in (pre)neoplastic lesions in rat liver. J Histochem Cytochem 51, 105-112. (Pubitemid 36133491)
217. Muir GG, Canti G, &, Williams D, (1964) Use of 6-phosphogluconate dehydrogenase as a screen test for cervical carcinoma in normal women. Br Med J 2, 1563-1565.
218. Bonham DG, &, Gibbs DF, (1962) A new enzyme test for gynaecological cancer. 6-Phosphogluconate dehydrogenase activity in vaginal fluid. Br Med J 2, 823-824.
219. Nerurkar VR, Ishwad CS, Seshadri R, Naik SN, &, Lalitha VS, (1990) Glucose-6-phosphate dehydrogenase and 6-phosphogluconate dehydrogenase activities in normal canine mammary gland and in mammary tumours and their correlation with oestrogen receptors. J Comp Pathol 102, 191-195. (Pubitemid 20111807)
220. Losman MJ, Rimon D, Kim M, &, Becker MA, (1985) Selective expression of phosphoribosylpyrophosphate synthetase superactivity in human lymphoblast lines. J Clin Invest 76, 1657-1664. (Pubitemid 16193589)
221. Coy JF, Dressler D, Wilde J, &, Schubert P, (2005) Mutations in the transketolase-like gene TKTL1: clinical implications for neurodegenerative diseases, diabetes and cancer. Clin Lab 51, 257-273. (Pubitemid 40895125)
222. Heinrich PC, Morris HP, &, Weber G, (1976) Behavior of transaldolase (EC 2.2.1.2) and transketolase (EC 2.2.1.1). Activities in normal, neoplastic, differentiating, and regenerating liver. Cancer Res 36, 3189-3197.
223. Hu LH, Yang JH, Zhang DT, Zhang S, Wang L, Cai PC, Zheng JF, &, Huang JS, (2007) The TKTL1 gene influences total transketolase activity and cell proliferation in human colon cancer LoVo cells. Anticancer Drugs 18, 427-433. (Pubitemid 46712406)
224. Zhang S, Yang JH, Guo CK, &, Cai PC, (2007) Gene silencing of TKTL1 by RNAi inhibits cell proliferation in human hepatoma cells. Cancer Lett 253, 108-114. (Pubitemid 46874727)
225. Liu H, Huang D, McArthur DL, Boros LG, Nissen N, &, Heaney AP, (2010) Fructose induces transketolase flux to promote pancreatic cancer growth. Cancer Res 70, 6368-6376.
226. Basta PV, Bensen JT, Tse CK, Perou CM, Sullivan PF, &, Olshan AF, (2008) Genetic variation in Transaldolase 1 and risk of squamous cell carcinoma of the head and neck. Cancer Detect Prev 32, 200-208.
227. Everson GT, &, Polokoff MA, (1986) HepG2. A human hepatoblastoma cell line exhibiting defects in bile acid synthesis and conjugation. J Biol Chem 261, 2197-2201. (Pubitemid 17205148)
228. Gygi SP, Rochon Y, Franza BR, &, Aebersold R, (1999) Correlation between protein and mRNA abundance in yeast. Mol Cell Biol 19, 1720-1730. (Pubitemid 29098230)
229. Moxley JF, Jewett MC, Antoniewicz MR, Villas-Boas SG, Alper H, Wheeler RT, Tong L, Hinnebusch AG, Ideker T, Nielsen J, et al. (2009) Linking high-resolution metabolic flux phenotypes and transcriptional regulation in yeast modulated by the global regulator Gcn4p. Proc Natl Acad Sci USA 106, 6477-6482.
230. Griffin ME, Hamilton BJ, Roy KM, Du M, Willson AM, Keenan BJ, Wang XW, &, Nichols RC, (2004) Post-transcriptional regulation of glucose transporter-1 by an AU-rich element in the 3'UTR and by hnRNP A2. Biochem Biophys Res Commun 318, 977-982. (Pubitemid 38625870)
231. Weinberg R, (2010) Point: Hypotheses first. Nature 464, 678.
232. Venkatasubramanian R, Henson MA, &, Forbes NS, (2008) Integrating cell-cycle progression, drug penetration and energy metabolism to identify improved cancer therapeutic strategies. J Theor Biol 253, 98-117.
233. Resendis-Antonio O, Checa A, &, Encarnacion S, (2010) Modeling core metabolism in cancer cells: surveying the topology underlying the Warburg effect. PLoS ONE 5, e12383.
234. Rapoport TA, Heinrich R, &, Rapoport SM, (1976) The regulatory principles of glycolysis in erythrocytes in vivo and in vitro. A minimal comprehensive model describing steady states, quasi-steady states and time-dependent processes. Biochem J 154, 449-469.
235. Teusink B, Passarge J, Reijenga CA, Esgalhado E, van der Weijden CC, Schepper M, Walsh MC, Bakker BM, van Dam K, Westerhoff HV, et al. (2000) Can yeast glycolysis be understood in terms of in vitro kinetics of the constituent enzymes? Testing biochemistry. Eur J Biochem 267, 5313-5329.
236. Guzy RD, Hoyos B, Robin E, Chen H, Liu L, Mansfield KD, Simon MC, Hammerling U, &, Schumacker PT, (2005) Mitochondrial complex III is required for hypoxia-induced ROS production and cellular oxygen sensing. Cell Metab 1, 401-408. (Pubitemid 43960623)
237. Carew JS, &, Huang P, (2002) Mitochondrial defects in cancer. Mol Cancer 1, 9.
238. Trachootham D, Zhou Y, Zhang H, Demizu Y, Chen Z, Pelicano H, Chiao PJ, Achanta G, Arlinghaus RB, Liu J, et al. (2006) Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by beta-phenylethyl isothiocyanate. Cancer Cell 10, 241-252. (Pubitemid 44311067)
239. Weinberg F, Hamanaka R, Wheaton WW, Weinberg S, Joseph J, Lopez M, Kalyanaraman B, Mutlu GM, Budinger GR, &, Chandel NS, (2010) Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity. Proc Natl Acad Sci USA 107, 8788-8793.